Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2013/053292external-prioritypatent/WO2013160873A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of CU20140122A7publicationCriticalpatent/CU20140122A7/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invención se refiere a los compuestos de la fórmula (I): útiles para el tratamiento de los trastornos mediados por acil-transferasa de acil-CoA-diacil-glicerol 1 ( DGAT1 ), por ejemplo, los trastornos metabólicos. La invención también proporciona métodos para el tratamiento de los trastornos, y los compuestos y las composiciones etc. para su tratamiento.The invention relates to the compounds of the formula (I): useful for the treatment of acyl-CoA-diacyl-glycerol 1 (DGAT1) mediated disorders, for example, metabolic disorders. The invention also provides methods for the treatment of disorders, and the compounds and compositions etc. for your treatment
CU2014000122A2013-03-152014-10-27
DGAT1 INHIBITORS OF CYCLIC HEAD OF BRIDGE HEAD
CU20140122A7
(en)
DERIVATIVES OF 3-ACETYLLAMIN-1 (PHENYL-HETEROARIL- AMINOCARBONIL OR PHENYL-HETEROARIL-CARBONYLAMINE) BENZENE FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS